Palivizumab
Category: VaccinationPalivizumab Overview
Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections.[2][3] It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease.[2][3] The most common side effects include fever and rash.[2][3]...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Palivizumab
Recent Palivizumab Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Palivizumab
- Injection: 100mg, 100mg/ml, 50mg, 50mg/ml
- Vial: 100mg/vial, 50mg/vial
Other drugs which contain Palivizumab or a similar ingredient: (1 result)
- SYNAGIS Palivizumab